United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares
by Sarita Garza · The Markets DailyUnited Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,908,251.64. The trade was a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Edgemond also recently made the following trade(s):
- On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Price Performance
Shares of United Therapeutics stock opened at $571.73 on Friday. The stock’s 50-day moving average is $516.68 and its 200 day moving average is $484.30. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The firm has a market cap of $25.06 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.65 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the business earned $6.19 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently weighed in on UTHR. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Wells Fargo & Company upped their price target on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Raymond James Financial began coverage on United Therapeutics in a research note on Friday. They set an “outperform” rating and a $700.00 price target on the stock. Finally, Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.
Read Our Latest Report on UTHR
Institutional Trading of United Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.